Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?

Current oncology reports - 16 Jul 2021

Luchini Claudio, Lawlor Rita T, Bersani Samantha, Vicentini Caterina, Paolino Gaetano, Mattiolo Paola, Pea Antonio, Cingarlini Sara, Milella Michele, Scarpa Aldo

Abstract excerpt

PURPOSE OF REVIEW: Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by some types of malignancies, including pancreatic neuroendocrine tumors, to overcome the issue of telomere shortening, thus supporting tumor growth and cell proliferation. This review is focused on the most important achievements and opportunities deriving from ALT assessment in PanNET onco-pathology,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Co-Repressor Proteins
Share to In Situ Hybridization, Fluorescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Chaperones

Share to Neuroendocrine Tumors

Share to Pancreatic Neoplasms

Share to Telomere

Share to Telomere Homeostasis

Share to X-linked Nuclear Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 34269919
DOI: 10.1007/s11912-021-01096-w
PMCID: PMC8285324

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?PMID 34269919Read ↗

Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.Semantic proximity Read ↗

Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine TumorsSemantic proximity Read ↗

Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical WorkupSemantic proximity Read ↗

The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumorsSemantic proximity Read ↗

Immunohistochemistry based molecular subtyping of pancreatic neuroendocrine tumor correlates with clinicopathological outcome: A single institute retrospective studySemantic proximity Read ↗

Neoplastic Progression in Neuroendocrine Neoplasms of the Pancreas.Semantic proximity Read ↗

Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort.Semantic proximity Read ↗

Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour sizeSemantic proximity Read ↗

Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translationSemantic proximity Read ↗

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.Semantic proximity Read ↗

ALT Positivity in Human Cancers: Prevalence and Clinical InsightsSemantic proximity Read ↗

Altered telomeres in tumors with ATRX and DAXX mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.